This article is presented at the 89th Annual Meeting of the American Radium Society, Amsterdam.
High-dose-rate brachytherapy plus neck dissection for nodal disease†
Article first published online: 7 MAR 2008
Copyright © 2008 Wiley Periodicals, Inc.
Head & Neck
Volume 30, Issue 7, pages 933–938, July 2008
How to Cite
Beitler, J. J., Garg, M., Owen, R. P., Sarta, C., Smith, R. V. and Yaparpalvi, R. (2008), High-dose-rate brachytherapy plus neck dissection for nodal disease. Head Neck, 30: 933–938. doi: 10.1002/hed.20799
- Issue published online: 9 JUN 2008
- Article first published online: 7 MAR 2008
- Manuscript Accepted: 9 NOV 2007
Vol. 31, Issue 3, 427, Article first published online: 20 JAN 2009
- neck disease;
- neck dissection regional control
Regional control for advanced nodal disease has been only marginally affected by concurrent chemoradiation, hyperfractionation, concomitant boost, or accelerated external radiation.
Twenty-five necks in 24 patients received brachytherapy treatment (20 Gy in 10 twice-daily fractions) in addition to external radiation, neck dissection ± chemotherapy. Indications for brachytherapy included initial treatment of bulky disease (n = 12), recurrence of neck disease in a previously treated patient with at least a 3-month disease-free interval (n = 6), persistent disease after a curative efforts (n = 4), inadequate external radiation (ie, <40 Gy) due to either intolerance or noncompliance (n = 3).
Overall actuarial regional control was 67% at 2 years. Regional control for those receiving brachytherapy as part of their initial treatment was 82% despite a mean nodal diameter of 8.7 cm (range, 5–15 cm). The 2-year actuarial regional control was 56% for the patients with a disease-free interval of at least 3 years.
High-dose-rate brachytherapy produced excellent regional control. © 2008 Wiley Periodicals, Inc. Head Neck, 2008